About Medtronic plc
https://www.medtronic.comMedtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide.
CEO
Geoffrey Straub Martha
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 1999-09-27 | Forward | 2:1 |
| 1997-09-15 | Forward | 2:1 |
ETFs Holding This Stock
VTS.AX
Weight:0.20%
Shares:40.26M
XUS.TO
Weight:0.22%
Shares:16.43M
IVV.AX
Weight:0.22%
Shares:16.43M
Summary
Showing Top 3 of 409
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Citigroup
Buy
Argus Research
Buy
RBC Capital
Outperform
Bernstein
Outperform
Mizuho
Outperform
Evercore ISI Group
Outperform
Grade Summary
Showing Top 6 of 17
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:127.07M
Value:$12.55B
BLACKROCK, INC.
Shares:119.57M
Value:$11.81B
BLACKROCK INC.
Shares:111.89M
Value:$11.05B
Summary
Showing Top 3 of 2,895
About Medtronic plc
https://www.medtronic.comMedtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2026 | $8.96B ▲ | $3.72B ▲ | $1.37B ▲ | 15.33% ▲ | $1.07 ▲ | $2.37B ▲ |
| Q1-2026 | $8.58B ▼ | $3.5B ▼ | $1.04B ▼ | 12.12% ▲ | $0.81 ▼ | $2.23B ▼ |
| Q4-2025 | $8.93B ▲ | $4.34B ▲ | $1.06B ▼ | 11.84% ▼ | $0.82 ▼ | $2.27B ▼ |
| Q3-2025 | $8.29B ▼ | $3.87B ▲ | $1.29B ▲ | 15.61% ▲ | $1.01 ▲ | $2.4B ▼ |
| Q2-2025 | $8.4B | $3.86B | $1.27B | 15.11% | $0.99 | $2.44B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2026 | $8.33B ▲ | $91.35B ▲ | $42.49B ▼ | $48.65B ▲ |
| Q1-2026 | $8.12B ▼ | $90.97B ▼ | $42.84B ▼ | $47.89B ▼ |
| Q4-2025 | $8.96B ▲ | $91.68B ▲ | $43.42B ▲ | $48.02B ▼ |
| Q3-2025 | $7.92B ▼ | $89.97B ▼ | $40.36B ▼ | $49.39B ▲ |
| Q2-2025 | $7.99B | $90.04B | $41.33B | $48.49B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2026 | $1.37B ▲ | $925M ▼ | $-482M ▲ | $-395M ▲ | $-1.27B ▲ | $457M ▼ |
| Q1-2026 | $1.05B ▼ | $1.09B ▼ | $-719M ▼ | $-1.38B ▼ | $-2.22B ▼ | $584M ▼ |
| Q4-2025 | $1.06B ▼ | $2.53B ▼ | $-490M ▲ | $-1.34B ▲ | $978M ▲ | $2.07B ▼ |
| Q3-2025 | $1.29B ▲ | $2.57B ▲ | $-843M ▼ | $-1.75B ▼ | $-154M ▼ | $2.1B ▲ |
| Q2-2025 | $1.28B | $958M | $-345M | $-534M | $83M | $554M |
Revenue by Products
| Product | Q2-2025 | Q4-2025 | Q3-2025 | Q1-2026 |
|---|---|---|---|---|
 Cardiac and Vascular Group | $3.10Bn ▲ | $3.33Bn ▲ | $3.04Bn ▼ | $3.29Bn ▲ |
 Diabetes Group | $690.00M ▲ | $730.00M ▲ | $690.00M ▼ | $720.00M ▲ |
 Medical Surgical | $2.13Bn ▲ | $2.21Bn ▲ | $2.07Bn ▼ | $2.08Bn ▲ |
 Neuroscience Group | $2.45Bn ▲ | $2.62Bn ▲ | $2.46Bn ▼ | $2.42Bn ▼ |
Revenue by Geography
| Region | Q4-2025 | Q2-2025 | Q3-2025 | Q1-2026 |
|---|---|---|---|---|
 IRELAND | $30.00M ▲ | $30.00M ▲ | $30.00M ▲ | $30.00M ▲ |
 Total Other Countries Excluding United States and Ireland | $4.35Bn ▲ | $4.07Bn ▼ | $4.03Bn ▼ | $4.32Bn ▲ |
 UNITED STATES | $4.55Bn ▲ | $4.30Bn ▼ | $4.24Bn ▼ | $16.88Bn ▲ |
CEO
Geoffrey Straub Martha
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 1999-09-27 | Forward | 2:1 |
| 1997-09-15 | Forward | 2:1 |
ETFs Holding This Stock
VTS.AX
Weight:0.20%
Shares:40.26M
XUS.TO
Weight:0.22%
Shares:16.43M
IVV.AX
Weight:0.22%
Shares:16.43M
Summary
Showing Top 3 of 409
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Citigroup
Buy
Argus Research
Buy
RBC Capital
Outperform
Bernstein
Outperform
Mizuho
Outperform
Evercore ISI Group
Outperform
Grade Summary
Showing Top 6 of 17
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:127.07M
Value:$12.55B
BLACKROCK, INC.
Shares:119.57M
Value:$11.81B
BLACKROCK INC.
Shares:111.89M
Value:$11.05B
Summary
Showing Top 3 of 2,895